1.Candida albicans promotes malignant progression of oral leukoplakia: a preliminary study based on clinical cohort and animal models
CHENG Fangbo ; ZHANG Shiyu ; WANG Ying ; LI Jing
Journal of Prevention and Treatment for Stomatological Diseases 2026;34(3):237-245
Objective:
To explore the correlation between Candida albicans and the development of oral leukoplakia (OLK), and to provide a basis for improving the pathogenic mechanism of the malignant transformation of OLK.
Methods:
Oral microbiome data were obtained from public databases (NCBI BioProject, PRJNA788378; GEO, GSE227919), and bioinformatic methods were employed to evaluate the correlation between Candida albicans infection and OLK. Approval was obtained from the institutional Medical Ethics Committee. A tissue microarray was constructed using samples collected from an OLK clinical cohort. Hematoxylin and eosin (H&E) staining and periodic acid-Schiff (PAS) staining were performed to analyze the relationship between the Candida albicans detection rate and clinicopathological features. Approval was obtained from the institutional Animal Ethics Committee. A mouse model was established by combining 4-nitroquinoline-1-oxide (4NQO) in drinking water with oral inoculation of Candida albicans (4NQO + Candida albicans group), while mice treated with 4NQO in drinking water and PBS served as the control group (4NQO + PBS group). The degree of epithelial dysplasia was compared between the two groups to assess the impact of Candida albicans infection on lesion progression (defined in this study as the progression from mild/moderate epithelial dysplasia to severe dysplasia/carcinoma in situ or invasive squamous cell carcinoma).
Results:
Bioinformatic analysis revealed that the detection rate of Candida albicans in OPMDs and OLK tissues was significantly higher than that in the healthy control group. Staining results of clinical samples demonstrated that Candida albicans colonized OLK lesions; compared with Candida albicans-negative patients, positive patients exhibited a state of high-grade progression. Animal experiments indicated that, compared with the 4NQO + PBS group, the degree of oral epithelial dysplasia in the 4NQO + Candida albicans group was significantly exacerbated, and the malignant transformation rate was higher, suggesting that Candida albicans promotes the high-grade progression of OLK.
Conclusion
Candida albicans exhibits a increasing trend during the malignant progression of the OLK. It aggravates the degree of epithelial dysplasia in OLK and promotes its transformation into high-grade lesions, suggesting that Candida albicans plays a crucial promoting role in the high-grade progression of OLK.
2.Mechanism of Jinshui Huanxian Component Formula Ⅱ Combined with Matrix Softening in Ameliorating Pulmonary Fibrosis Through Inhibition of Epithelial-mesenchymal Transition
Xiaojie WU ; Mingyan LI ; Shiyu KUANG ; Xiling PENG ; Xiaorong HOU ; Han LIU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(18):108-121
ObjectiveTo determine whether Jinshui Huanxian component formula Ⅱ (ECC-JHF Ⅱ) and matrix hardness interfere with the process of epithelial-mesenchymal transition (EMT) during pulmonary fibrosis by regulating integrin β1 (ITG β1), and to elucidate the underlying mechanism. MethodsA pulmonary fibrosis mouse model was established by a single intratracheal instillation of bleomycin (BLM). To observe the disease progression at various time points, the mice were sacrificed before modeling and on days 7, 14, 21, 28 and 42 after modeling for assessment of relevant indicators. To evaluate the therapeutic effect of drug intervention, the mice were given ECC-JHF Ⅱ and pirfenidone (PFD) by gavage starting on day 29 after modeling for 14 days of treatment, after which the mice were sacrificed. Pulmonary function, pathological changes, collagen deposition, lung tissue hardness and EMT markers were detected. Polyethylene glycol (PEG) composite hydrogels with different hardness were prepared in vitro using biomaterials such as eight-arm polyethylene glycol thiol (PEG-SH) and eight-arm polyethylene glycol maleimide (PEG-MAL). Human type Ⅱ alveolar epithelial cells cultured in hard matrix culture dishes were treated with low, medium, and high doses of ECC-JHF Ⅱ (15.31, 30.63, 61.25 mg·L-1) to observe the intervention effect of ECC-JHF Ⅱ on EMT induced by transforming growth factor beta 1 (TGF-β1). Human type Ⅱ alveolar epithelial cells cultured on soft (3.8 kPa) and hard (culture dishes, ~ GPa) matrices were treated with ECC-JHF Ⅱ, respectively. The mRNA and fluorescence expression levels of the epithelial marker E-cadherin (CDH1), the mesenchymal marker N-cadherin (CDH2) and vimentin (VIM), as well as ITG β1, were detected by real-time quantitative polymerase chain reaction (Real-time PCR) and immunofluorescence. Western blot was used to detect the protein expression of CDH1, CDH2 and ITG β1, and the biomechanical mechanism of ECC-JHF Ⅱ on EMT and pulmonary fibrosis was further verified by knocking down and specific activation of ITG β1. ResultsECC-JHF Ⅱ treatment improved BLM-induced pulmonary fibrosis in mice, as evidenced by significantly increased minute ventilation (MV) and 50% expiratory flow at tidal volume (EF50) (P<0.05), and significantly increased tidal volume (TV) after treatment (P<0.01) compared with the model group. Immunohistopathological analysis revealed attenuated inflammation and alveolar injury, reduced deposition of type Ⅰ collagen (Col-Ⅰ), and significantly decreased lung tissue stiffness (P<0.01), thereby alleviating disease progression. The real-time PCR results showed that, compared with the model group, the ECC-JHF Ⅱ group showed increased CDH1 expression and decreased CDH2 and VIM expression in mouse lung tissues (P<0.05, P<0.01), indicating that ECC-JHF Ⅱ inhibited the EMT process to ameliorate pulmonary fibrosis. In vitro experimental results showed that both ECC-JHF Ⅱ and matrix softening reversed the EMT phenotype switch. Specifically, compared with the hard matrix group, the cells cultured on the soft matrix exhibited significantly upregulated expression of the epithelial marker CDH1 (P<0.01) and significantly downregulated expression of the mesenchymal markers CDH2 and VIM (P<0.05). Furthermore, ECC-JHF Ⅱ inhibited the expression of ITG β1 both in vitro and in vivo. Knockdown and specific activation of ITG β1 further confirmed that ITG β1 is involved in the regulatory process by which ECC-JHF Ⅱ inhibits EMT and ameliorates pulmonary fibrosis
3.Carthamus tinctorius L.-derived nanovesicles alleviate cardiomyocyte hypertrophy by inhibiting the NF-κB signaling pathway
Guojun ZHANG ; Zhongpeng DU ; Lu WANG ; Junyu CHEN ; Huanjun RUAN ; Ye LUO ; Weili DUAN ; Shiyu CHEN ; Teng LI ; Xiao KE
Acta Universitatis Medicinalis Anhui 2026;61(8):1416-1423
ObjectiveTo investigate whether Carthamus tinctorius L.-derived nanovesicles (CDNVs) can alleviate angiotensin Ⅱ (ANGⅡ)-induced cardiomyocyte (H9C2) hypertrophy by inhibiting the NF-κB signaling pathway and to elucidate the underlying molecular mechanisms. MethodsCDNVs were isolated and purified by ultracentrifugation combined with sucrose density gradient centrifugation, and their morphology and particle size distribution were identified by transmission electron microscopy and nanoparticle tracking analysis. Rat H9C2 cardiomyocytes were cultured in vitro and randomly divided into the normal control group (NC), ANGⅡ (1.0 μmol/L) group, ANGⅡ+CDNVs group, and ANGⅡ+CDNVs+NF-κB activator 1 group. After 24 h of intervention, cell viability was detected by the CCK-8 assay, the expression of myocardial hypertrophy-related genes (ANP, BNP) was determined by qPCR, the relative cell area was measured by phalloidin staining, the expression of hypertrophy marker proteins and NF-κB pathway proteins (P-p65/p65, P-IκBα/IκBα) was examined by Western blot, and nuclear translocation of p65 was observed by immunofluorescence. Subsequently, NF-κB signaling pathway agonist activator 1 was added, and the expression of myocardial hypertrophy marker proteins and NF-κB pathway proteins was detected. ResultsCDNVs exhibited a typical round-like vesicle structure with an average particle size of 140.4 nm, which was consistent with the morphological characteristics of exosomes. ANGⅡ at concentrations of 0.1-1.0 μmol/L had no significant effect on cardiomyocyte viability. Compared with the NC group, ANGⅡ significantly upregulated the gene expression of ANP and BNP, increased the relative surface area of cardiomyocytes, elevated the levels of myocardial hypertrophy marker proteins and NF‑κB pathway proteins, and promoted the nuclear translocation of p65 (P<0.05). Following treatment with CDNVs, all the above indicators were markedly reduced in comparison with the ANGⅡ group (all P<0.05). However, all these experimental results were reversed after the addition of an NF‑κB agonist. ConclusionCDNVs alleviate ANGⅡ-induced H9C2 cell hypertrophy by inhibiting the NF-κB signaling pathway.
4.Mechanism of Yiqi yangyin huazhuo tongluo formula in ameliorating diabetic kidney disease by regulating the gut microbiota-LPS/Caspase-11/GSDMD pathway
Zijun HOU ; Yingli LI ; Kelei GUO ; Yiyuan WANG ; Shiyu HUANG ; Lujia ZHANG ; Hua BIAN
China Pharmacy 2026;37(19):2536-2543
OBJECTIVE To explore the mechanism of Yiqi yangyin huazhuo tongluo formula in ameliorating diabetic kidney disease (DKD) based on the gut microbiota-lipopolysaccharide (LPS)/Caspase-11/gasdermin D (GSDMD) pathway.METHODS A DKD mouse model was established by high-fat and high-sugar diet combined with intraperitoneal injection of low-dose streptozotocin. The successfully modeled mice were randomly divided into model group, metformin group (positive control, 200 mg/kg) and Yiqi yangyin huazhuo tongluo formula group (32.4 g/kg, calculated as crude drug dosage), with 10 mice in each group; another 10 mice were set as the control group. Mice were intragastrically administered with corresponding drug solutions or normal saline once a day for 8 consecutive weeks. After the last administration, serum glycolipid metabolism indicators and urinary renal function indicators of mice were determined; the pathological and morphological changes of renal and colonic tissues were observed; LPS contents in renal tissues, colonic contents and serum were detected. 16S rRNA high-throughput sequencing was performed for gut microbiota analysis of colonic contents. The protein expressions of Occludin and zonula occludens-1 (ZO-1) in colonic tissues as well as Caspase-11 and GSDMD in renal tissues were detected.RESULTS Compared with the control group, the model group exhibited significantly elevated levels of serum fasting blood glucose, triglyceride, total cholesterol, serum creatinine, blood urea nitrogen and microalbumin, LPS contents in each sample, as well as protein expressions of Caspase-11 and GSDMD in renal tissues ( P <0.05). The protein expressions of ZO-1 and Occludin in colonic tissues, together with Chao1 and Ace indices of gut microbiota, were markedly decreased ( P <0.05), and the ratio of Firmicutes to Bacteroidetes was abnormally increased. Obvious histopathological changes were observed in renal and colonic tissues; the percentage of PAS-positive area in kidney was markedly increased ( P <0.05). Compared with the model group, the Yiqi yangyin huazhuo tongluo formula group showed remarkable reductions in glycolipid metabolism and renal function-related indicators(except total cholesterol), LPS contents in various samples, and renal protein expressions of Caspase-11 and GSDMD ( P <0.05). The protein expression level of ZO-1 in colonic tissues and the Ace index of gut microbiota were significantly increased ( P <0.05), and the relative abundance of beneficial genera including Bifidobacterium , Faecalibaculum and Akkermansia in the gut microbiota was elevated.CONCLUSIONS The mechanism by which Yiqi yangyin huazhuo tongluo formula ameliorates DKD may be related to reshaping gut microbiota, repairing intestinal mucosal barrier, reducing LPS translocation into blood, and further inhibiting Caspase-11/GSDMD-mediated pyroptosis in kidney.
5.Analysis of the current status and influencing factors of frailty in patients aged 75 and above after percutaneous coronary intervention
Yang CHEN ; Shiyu WANG ; Chuan GAO ; Wenqing CAI ; Yajing SU ; Yumeng ZHANG ; Qingyin LI
Chinese Journal of Nursing 2025;60(13):1588-1595
Objective To evaluate the frailty status and risk factors among hospitalized elderly patients after percutaneous coronary intervention(PCI),and to provide a reference for improving and delaying their frailty.Methods From March to August 2024,using convenience sampling,patients aged over 75 years who underwent PCI in a tertiary cardiovascular disease specialist hospital in Beijing were selected as the survey participants.Patient-related informations were collected through a self-designed general information questionnaire.The Fried Phenotype Frailty Scale,the Katz Activities of Daily Living,Lawton Instrumental Activities of Daily Living(IADL)scale,the Charlson Comorbidity Index,the Morse Fall Scale,the Mini Nutritional Assessment-Short Form(MNA-SF),and the 15-item Geriatric Depression Scale(GDS-15)were evaluated postoperatively until discharge.Univariate and multivariate logistic analyses were conducted to identify factors associated with frailty among patients after PCI.Results A total of 278 patients were included.The incidence of frailty after PCI was 52.16%.Based on Fried Phenotype scores,patients were divided into a non-frail group and a frail group.Univariate analysis showed statistically significant differences between the 2 groups in terms of age,gender,hemoglobin,NT-ProBNP,LVEF,IADL scores,living alone status,nutrition status,falls risk,and depression level(P<0.05).Multivariate logistic regression analysis revealed that age,Lawton IADL scores,falls risk,nutrition status,depression level were factors influencing frailty,with odds ratios of 1.167,0.575,1.597,0.399,and 3.610,respectively(P<0.05).Conclusion The incidence of frailty is high among patients aged over 75 years after PCI,and there are multiple risk factors affecting their frailty status.Clinical healthcare providers should prioritize long-term management of these patients and implement comprehensive interventions with the consideration of their physiological,psychological,and social conditions.
6.Epidemiological Characteristics of Oral and Pharyngeal Cancer in Hunan Cancer Registration Areas in 2021 and Trends from 2012 to 2021
Can LI ; Yanhua ZOU ; Haifan XIAO ; Yingyun HU ; Zhaohui SHI ; Shiyu CAO ; Senmao ZHANG ; Shipeng YAN
China Cancer 2025;34(11):854-861
[Purpose]To analyze the incidence and mortality of oral and pharyngeal cancer in can-cer registration areas of Hunan Province in 2021 and the trend changes from 2012 to 2021.[Methods]Data on oral and pharyngeal cancer incidence and mortality from 2012 to 2021 were collected from 78 quality-controlled cancer registries in Hunan Province,with population data sourced from household registration statistics provided by public security authorities.Indicators such as crude incidence and mortality rates,age-standardized incidence and mortality rates by Chinese standard population(ASIRC/ASMRC),and world standard population(ASIRW,ASMRW)in 2021 were calculated.The Chinese standard population(2000 national census)and Segi's world standard population were used for standardization.Joinpoint Regression Program 4.9.0.0 software was used to fit a Log-linear regression model,and the average annual percentage change(AAPC)of ASIRC/ASMRC of oral and pharyngeal cancer from 2012 to 2021 was calculated to analyze the changing trends.[Results]In 2021,the crude incidence rate of oral and pharyngeal cancer in cancer registration areas of Hunan Province was 9.28/105(15.14/105 for males and 3.07/105 for fe-males),with an ASIRC of 6.10/105;the crude mortality rate was 3.75/105(6.19/105 for males and 1.16/105 for females),with an ASMRC of 2.16/105.Both the incidence and mortality rates in male were significantly higher than those in female.Age distribution analysis showed that the incidence rate of oral and pharyngeal cancer increased with age after 30 years old,peaking in the age group of 60~64 years old(22.29/105);the mortality rate continued to rise after 35 years old,reaching the peak in the population aged ≥85 years old(14.52/105).Trend analysis from 2012 to 2021 indicated that the crude incidence rate and ASIRC of oral and pharyngeal cancer increased from 3.50/105 and 2.63/105 in 2012 to 9.28/105 and 6.10/105 in 2021,with AAPC of 12.33%and 10.80%,re-spectively;the crude mortality rate and ASMRC also showed upward trends(AAPC of 9.87%and 7.21%,respectively);all trend changes were statistically significant(all P<0.05).Sex stratification revealed that the AAPC of ASIRC and ASMRC of oral and pharyngeal cancer in male were higher than those in female(AAPC of ASIRC:12.65%for males vs 4.28%for females;AAPC of ASMRC:8.79%for males vs 4.13%for females).Age-specific trend analysis found that the ASIRC of oral and pharyngeal cancer in the population aged ≤ 44 years old showed an upward trend(AAPC=11.73%,P<0.001),with the AAPC of male in this group reaching 14.57%;the AAPC of ASIRC for the age groups of 45~64 years old and ≥65 years old were 11.03%and 9.74%,respectively,and the AAPC of ASMRC for these two groups were 10.05%and 8.19%,respectively,with all trend changes being statistically significant(all P<0.05);there was no statistically significant change in the ASMRC of the population aged ≤44 years old(AAPC=5.66%,P=0.087).[Conclusion]The incidence and mortality rates of oral and pharyngeal cancer in cancer registration areas of Hunan Province remain high and show an upward trend,with a tendency of younger onset.Males and middle-aged and elderly populations are the key focuses of prevention and control.
7.Research progress of magnesium-based biomaterials in the treatment of bone defects induced by osteosarcoma
Jingteng CHEN ; Ling YU ; Shiyu LI ; Weichun GUO
Chinese Journal of Orthopaedics 2025;45(2):109-118
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents with a peak incidence between the ages of 10 and 20. It has an extremely high mortality and disability rate. In adults, osteosarcoma is the third most common bone tumor. Despite the advances in chemotherapy, surgical techniques, and radiotherapy that have significantly improved the overall survival rate of osteosarcoma, the long-term prognosis of patients has not shown substantial improvement, especially in cases of tumor metastasis and recurrence. Due to the highly invasive growth of tumor cells, the progression of osteosarcoma is often accompanied by the destruction of surrounding bone tissue and the formation of immature new bone, making treatment challenging, especially in tissue repair and functional recovery following surgical resection. Tumor resection surgery often results in extensive bone loss, particularly in cases involving joints or weight-bearing areas, making the reconstruction of bone structure and function highly complex. Currently, inert materials such as stainless steel or titanium alloy prostheses used in clinical practice exhibit poor biocompatibility and high elastic modulus, often leading to prosthesis loosening and infection. There is an urgent clinical need for multifunctional biomaterials capable of both repairing bone defects and inhibiting tumor recurrence. Magnesium-based biomaterials have shown excellent biodegradability and bioactivity, and the release of magnesium ions and degradation products effectively promotes bone tissue regeneration while demonstrating potential antitumor effects. This paper reviews the application of magnesium-based biomaterials in the treatment of bone defects associated with osteosarcoma, including their adaptation to the acidic conditions of the osteosarcoma microenvironment, their potential to promote osteogenesis, and their antitumor mechanisms. It also analyzes the mechanical compatibility of magnesium-based materials and the use of coating technologies to enhance their corrosion resistance, and explores the prospects of various types of magnesium-based compounds in the treatment of osteosarcoma-related bone defects.
8.Association of urinary serine protease Corin with clinical staging in early diabetic kidney disease
Wenqian TIAN ; Jingyi LU ; Danyang CHEN ; Sa LI ; Shiyu LIU ; Xiaoying ZHANG ; Wanjun PANG ; Yahui HU
Chinese Journal of Endocrinology and Metabolism 2025;41(2):120-128
Objective:To investigate the level of urinary serine protease(Corin) in early diabetic kidney disease(DKD) and its correlation with clinical stage.Methods:One hundred and seventy-three patients with type 2 diabetes mellitus(DM) from two tertiary A hospitals in Henan, diagnosed between April 2023 and December 2023 were selected as the research group, and 120 healthy subjects were selected as the control group. Basic clinical information and laboratory data were collected, and urinary Corin level was detected. DM patients were classified into G1-G5 stages based on estimated glomerular filtration rate(eGFR), and those in the early DKD stages(G1-G3) were further divided into A1-A3 subgroups based on urinary albumin/creatinine ratio(ACR). Spearman correlation analysis was performed to assess relationships between urinary Corin and other indicators, linear regression analysis identified factors influencing urinary Corin in early DKD patients, logistic regression analysis evaluated the risk factors for early DKD, and receiver operating characteristic(ROC) curve analysis determined the diagnostic value of urinary Corin in early DKD. Results:Urinary Corin levels were significantly higher in early DKD patients compared to healthy controls, with levels increasing as ACR rose( P<0.05). Urinary Corin was positively associated with serum creatinine( r=0.570), urea( r=0.458), cystatin C( r=0.693), ACR( r=0.616), urinary transferrin( r=0.448), urinary α1 microglobulin( r=0.507), urinary n-acetyl-β-D-glucosaminase( r=0.388) and A subgroup( r=0.692) while was negatively correlated with eGFR( r=-0.647), albumin( r=-0.312)(all P<0.05). eGFR was the only independent factor affecting urinary Corin. After adjusting for confounding factors in logistic regression analysis, urinary Corin was still an independent influencing factor for early DKD. ROC curve analysis indicated that urinary Corin had a diagnostic AUC of 0.842(95% CI 0.791-0.892, P<0.001), with a cut-off value of 2 226.04 pg/mL, sensitivity of 0.712, and specificity of 0.858 for early DKD diagnosis. Conclusions:Urinary Corin was elevated in early DKD patients and correlated with clinical stage. Urinary Corin is an independent factor of early DKD, and a reliable predictor of early DKD diagnosis.
9.Chronic hepatitis B long-term antiviral therapy:Reflections on suboptimal response and low-level viremia
Xin WEI ; Lilong CONG ; Linmei YAO ; Zixuan GAO ; Shuojie WANG ; Ziyu ZHANG ; Xinxin LI ; Shiyu WANG ; Wen DENG ; Minghui LI
Chinese Journal of Experimental and Clinical Virology 2025;39(4):518-525
Chronic hepatitis B(CHB)is one of the major challenges in the global public health field. As of 2022,approximately 254 million people worldwide were infected with the hepatitis B virus(HBV). CHB is one of the main causes of liver cirrhosis and hepatocellular carcinoma(HCC). Nucleos(t)ide analogs(NAs)and interferon therapy can delay the progression of liver fibrosis by inhibiting viral replication,but they cannot completely avoid the problem of heterogeneous treatment responses. Some patients are in a state of low-level viremia(LLV)during treatment. The persistent LLV state can induce chronic inflammation and the progression of liver fibrosis,ultimately increase the risk of HCC. In patients with poor treatment responses,the continuous active viral replication can induce immune disorders,accelerate the evolution of fibrosis to the decompensated stage of liver cirrhosis,and increase the risk of patient death. This article aims to review the definition,mechanisms,and impact on treatment outcomes of LLV and suboptimal response based on the latest research,provide a basis for optimizing antiviral therapy for CHB.
10.Machine Learning-Assisted Efficacy Evaluation of Resveratrol Therapy in a Mouse Model of Acute Pancreatitis
Ziyu LI ; Yuxing TIAN ; Wenhao CAI ; Yongzi WU ; Shiyu LIU ; Linbo YAO ; Yuying LI ; Xueying WU ; Tingting LIU ; Wei HUANG
Journal of Sichuan University (Medical Sciences) 2025;56(4):1051-1058
Objective To develop a machine learning(ML)-based prediction model for assessing the therapeutic effects of resveratrol(RES)on the pathological damage of acute pancreatitis(AP),and to optimize RES administration strategies for AP through validation using an animal model.Methods AAn ML-based prediction model was constructed using published data.Interpretability analysis was applied to identify high-efficacy zones within the parameter space of administration dose and frequency,which was followed by rigorous screening to select the optimal dosing strategy that balanced therapeutic efficacy and experimental feasibility.A total of 32 C57BL/6 mice were randomly assigned to 4 groups(n=8 per group),including a control group(Ctrl),an AP model group induced by caerulein(CER)and referred to as CER-AP,a treatment group receiving RES via intraperitoneal injection(RES i.p.),and a treatment group receiving RES via intragastric gavage(RES i.g.).The Ctrl group received intraperitoneal injection of normal saline.The CER-AP and the treatment groups were induced with 10 intraperitoneal injections of CER at 50 μg/kg.RES was administered to the RES i.p.and RES i.g.groups according to the optimal dose and timing predicted by the ML model.Blood and tissue samples were collected 12 hours after the experiment started.Results The gradient boosting decision tree model,optimized via Hyperopt,yielded the best performance,predicting that the optimal dose and administration frequency were 19.992 mg/kg and 3.828 times,respectively.Accordingly,a regimen of 20 mg/kg RES,administered four times,was used in the animal experiments.Compared with the Ctrl group,the CER-AP group exhibited higher pancreatic pathology scores and elevated levels of serum amylase,lipase,pancreatic myeloperoxidase,and trypsin,with all differences reaching statistical significance(all P<0.05).The administration of 20 mg/kg RES via both intraperitoneal injection and intragastric gavage mitigated pancreatic inflammatory cell infiltration and necrosis,improved the overall pathology score,and reduced serum amylase,lipase,and pancreatic myeloperoxidase levels to varying degrees(all P<0.05).Conclusion A regimen of 20 mg/kg RES administered four times effectively alleviates the severity of CER-induced AP.The therapeutic benefits appear to arise from a multi-target regulatory network that simultaneously suppresses inflammatory cascades,mitigates oxidative stress,and reduces apoptosis,thereby reducing pancreatic tissue damage and systemic inflammatory responses.


Result Analysis
Print
Save
E-mail